迪瑞医疗(300396) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥198,572,194.45, representing a 14.82% increase compared to ¥172,939,800.45 in the same period last year[9] - Net profit attributable to shareholders was ¥58,429,472.14, a significant increase of 53.93% from ¥37,958,679.00 in the previous year[9] - The net profit after deducting non-recurring gains and losses was ¥56,891,974.75, up 53.73% from ¥37,008,604.53 year-on-year[9] - The basic earnings per share increased to ¥0.2132, reflecting a growth of 53.94% compared to ¥0.1385 in the same period last year[9] - The gross profit margin improved significantly, with operating profit increasing by 41.33% to 66.64 million yuan compared to the same period last year[26] - The company's net profit for the first quarter of 2021 is not explicitly stated in the provided documents, but the increase in retained earnings to CNY 1,036,626,245.82 from CNY 978,196,773.68 suggests positive performance[50] - The total comprehensive income attributable to the parent company was ¥58,466,342.31, up from ¥37,957,273.05, marking a 54% increase[69] Cash Flow - The net cash flow from operating activities decreased by 56.06% to ¥17,958,783.92 from ¥40,868,720.89 in the previous year[9] - The company's cash flow from operating activities generated a net inflow of ¥17,958,783.92, down from ¥40,868,720.89 in the previous period[79] - The net cash flow from operating activities was 16,521,283.28, a decrease of 37.2% compared to the previous period's 26,337,419.33[84] - Cash inflow from operating activities totaled 197,163,125.00, up 5.4% from 187,586,356.18 in the prior period[84] - Cash outflow from operating activities increased to 180,641,841.72, compared to 161,248,936.85 in the previous period, reflecting a rise of 12.0%[84] - The net cash flow from investing activities was 58,580,603.00, a significant improvement from the previous period's negative cash flow of -66,591,152.41[87] - The ending cash and cash equivalents balance was 737,856,599.25, up from 266,380,236.57 in the prior period, representing a substantial increase of 176.5%[87] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,058,741,321.44, a 1.74% increase from ¥2,023,448,189.59 at the end of the previous year[9] - The company's total assets increased to ¥2,012,528,184.90, compared to ¥1,977,308,150.56 in the previous period, marking a growth of 1.8%[57] - The total current liabilities decreased to CNY 316,967,676.61 from CNY 339,060,982.42, a reduction of about 6.5%[47] - The total liabilities decreased to CNY 345,774,613.01 from CNY 368,947,823.47, a decline of about 6.3%[47] - Total liabilities decreased to ¥343,620,808.57 from ¥366,304,794.46, a reduction of 6.2%[57] Shareholder Equity - Net assets attributable to shareholders increased by 3.53% to ¥1,712,966,708.43 from ¥1,654,500,366.12 at the end of the previous year[9] - The company's total equity attributable to shareholders reached CNY 1,712,966,708.43, up from CNY 1,654,500,366.12, marking an increase of approximately 3.5%[50] - The company's equity increased to ¥1,668,907,376.33, up from ¥1,611,003,356.10, reflecting a growth of 3.6%[57] Operating Costs and Expenses - The company experienced a 37.25% increase in operating costs, amounting to 23.93 million yuan, driven by higher product sales and agency product sales[21] - Total operating costs amounted to ¥140,288,213.40, up from ¥129,831,791.49, reflecting a rise of 7.5%[62] - Research and development expenses for the current period were ¥20,115,688.19, down from ¥22,554,378.11, a decrease of 10.8%[62] - Management expenses decreased by 50.32%, down by 10.05 million yuan, as Ningbo Ruiyuan was no longer included in the consolidation scope[21] Market Expansion - The international market export business grew by 80%, accounting for over 30% of total revenue, indicating strong international market expansion[26] - The company plans to enhance its product export business further as localization policies in international markets are implemented[26] Other Financial Metrics - The weighted average return on equity was 3.47%, up from 2.46% in the same period last year[9] - The company received government subsidies amounting to ¥1,786,202.85 during the reporting period[9] - The total number of ordinary shareholders at the end of the reporting period was 10,342[12] - Investment income surged by 5.85 million yuan, marking a staggering increase of 903.60% year-on-year, attributed to equity method accounting for Ningbo Ruiyuan[22]